Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAN 10

Drug Profile

CAN 10

Alternative Names: CAN-10

Latest Information Update: 10 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lund University
  • Developer Cantargia
  • Class Anti-inflammatories; Antipsoriatics; Cardiovascular therapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1 inhibitors; Interleukin 36 inhibitors; Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myocarditis; Plaque psoriasis; Systemic scleroderma
  • Preclinical Atherosclerosis; Peritonitis; Psoriatic arthritis

Most Recent Events

  • 29 Nov 2024 Cantargia plans a phase II trial for Plaque psoriasis in H2 2025
  • 20 Oct 2023 Phase-I clinical trials in Myocarditis in Sweden (IV), prior to October 2023 (Cantargia pipeline, October 2023)
  • 20 Oct 2023 Phase-I clinical trials in Myocarditis in Sweden (SC), prior to October 2023 (Cantargia pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top